August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Leandro Jonata Carvalho Oliveira: Added Clinical Impact of the Oncotype DX Assay
Aug 6, 2025, 16:21

Leandro Jonata Carvalho Oliveira: Added Clinical Impact of the Oncotype DX Assay

Leandro Jonata Carvalho Oliveira, MD Medical Oncologist at Grupo Oncoclinicas. shared on LinkedIn about a recent paper published on ScienceDirect:

“Just out in The Breast: a multicenter, real-world study from GBECAM evaluating the added clinical impact of the Oncotype DX assay in HR+/HER2- early breast cancer.

In this retrospective analysis, a small and highly selected subgroup of patients – eligible for adjuvant CDK4/6i but with low/intermediate genomic risk by ODX-achieved excellent 5-year outcomes with ET alone:

  • 95-100% postmenopausal
  • 80% with only 1N+
  • Among monarchE-eligible: 70% met Cohort 2 only.

These findings underscore the importance of integrating biologic/genomic features into clinical/anatomic evaluation to refine risk stratification and guide personalized treatment decisions.

We still face an urgent need to expand access to genomic signatures for Brazilian patients with HR+/HER2- eBC.

My sincere thanks to GBECAM – Brazilian Group for Breast Cancer Studies, all co-authors and participating centers, and especially our senior author, Dr. Max Mano, for their invaluable contributions.”

Title: Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study

Authors: Leandro Jonata de Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, Daniele Assad-Suzuki, Daniel Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Aliosha Kaliks, Debora de Melo Gagliato, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Carlos Henrique dos Anjos, Rudinei Linck, Thais Baccili Cury Megid, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Max Senna Mano

Read the full article.

Leandro Jonata Carvalho Oliveira

More posts featuring Leandro Jonata Carvalho Oliveira.